#IAS2019: WHO gives blockbuster HIV drug the green light
Dolutegravir has been approved as a first-line and second-line treatment for women of childbearing age.
Read More » #IAS2019: WHO gives blockbuster HIV drug the green light
birth defects
Half of birth defects are preventable
It is believed that more than half of all birth defects can be prevented or treated, despite statistics showing that birth defects are the third highest cause of early deaths in the Western Cape.
Read More » Half of birth defects are preventable
New ARV not for women wanting to fall pregnant
AMSTERDAM - Dolutegravir, the new wonder antiretroviral (ARV) drug, should not be given to women who want to get pregnant, the World Health Organisation (WHO) warned this week.
Read More » New ARV not for women wanting to fall pregnantBirth defects fears prompt warnings about new ARV
Within a week the "revolutionary" new HIV drug dolutegravir has gone from panacea to pariah. Recent data from a Botswana study linking the drug to birth defects has seen the highest international health bodies issuing public warnings.
Read More » Birth defects fears prompt warnings about new ARV
Do more to address birth defects
SAHR 2016: SA has not reduced deaths of children under the age of five since 2011 as we have failed to address “congenital disorders”.
Read More » Do more to address birth defects